drugset / Trial / NCT05045053

Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

NCT05045053

Phase 4 Unknown 40 enrolled Benha University
RandomizedParallel-groupSingle-blindTreatment

Summary

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

Timeline

Start
2021-02-01
Primary completion
2022-01
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lifitegrast Unknown 0.5 % Other

Indications